Moussa81 Buying quality companies at reasonable prices remains a winning investment strategy in my opinion despite all the noise around high-flying Al names on the market today. What's even better is if those stocks pay you a decent yield for holding onto them, which makes natural price volatility easier to bear. This brings me to Medtronic (NYSE:MDT), which I last covered in August with a 'Buy' rating, noting its undervaluation, strong balance sheet, and positioning for international growth. Since my l ...

Altayb/E+ via Getty ImagesIntroduction Allow me to start this article by showing you a chart I have used quite a few times in the past few months. As we can see below, the market has a quite lofty valuation. The S&P 500 traded at 21x earnings going into this month. That's 1.3x its long-term standard deviation. In fact, it's the third-most expensive market since the early 1990s. Only the Dotcom and post-pandemic periods were more expensive. JPMorganThis does not mean that stocks are due for a massive sel ...

Medtronic (MDT) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this medical device company have returned -2.6% over the past month versus the Zacks S&P 500 composite's +1.6% change. The Zacks Medical - Products industry, to which Medtronic belongs, has lost 3% over this period. Now the key question is: Where could the stock be headed in the near term?While media relea ...

Medtronic plc (MDT) recently presented positive clinical trial safety and efficacy results for Sphere-360 -- an investigational single-shot mapping and ablation catheter using pulsed field (PF) energy The catheter is intended for treatment of patients with paroxysmal atrial fibrillation (AFib).The European Heart Rhythm Association (EHRA) 2024 Annual Meeting featured a late-breaking clinical trial showcasing interim findings from the first-in-human Sphere-360 investigation.About Sphere-360 CatheterThe Sphere ...

FN Media Group News Commentary PALM BEACH, Fla., April 10, 2024 /PRNewswire/ -- With the increase in life expectancy, people need more medical help and care. AI-enabled technologies can help people to live healthier and longer lives. Artificial Intelligence (A.I.) has a great demand in the healthcare industry. Healthcare providers turn to tech companies for expertise in adopting AI, and naturally, demand for such expertise makes competition among the latter highly intensive.  A report from binariks.com pro ...

AI-driven solutions and strategic alliances showcase Medtronic's promise to enhance the efficiency and effectiveness of endoscopy DUBLIN, April 10, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, announced the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system, along with a strategic collaboration designed to enhance patient care. GI Genius™ wa ...

EHRA late-breaking data: Results highlight efficacy, safety, and durability of the novel PFA catheter that is fully integrated with Affera™ Mapping and Ablation SystemDUBLIN and BERLIN, April 8, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced positive clinical trial safety and efficacy results for Sphere-360™, an investigational single-shot mapping and ablation catheter using pulsed field (PF) energy, for treatment of patients with paroxysmal atrial ...

New data from largest head-to-head randomized control TAVR trial demonstrates non-inferior clinical outcomes and superior valve performance for Evolut TAVR compared to Sapien™ at one year DUBLIN and ATLANTA, April 7, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced new data from the largest head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (TAVR), were presented as a late breaking clinical trial at the American Coll ...

Core Insights - Medtronic's survey reveals significant gaps in awareness and referral for heart valve disease among women aged 50 and older, particularly those at risk for aortic stenosis [1][2][3] Awareness and Knowledge - 26% of women have not heard of common heart-related conditions, and only 30% of women aged 50 and older are aware of aortic stenosis [3] - Awareness is notably lower among women of color, with only 10% of Black women and 21% of Hispanic women aware of aortic stenosis compared to 33% of white women [3] Referral and Screening - 82% of women over 65 live with chronic conditions that increase their risk of aortic stenosis, yet 68% have never been referred to a cardiologist or undergone a heart disease risk assessment [3] Barriers to Seeking Care - Over 40% of women cite fear or anxiety about visiting a doctor, and 15% feel their symptoms will be dismissed [4] Treatment Preferences - 45% of women prioritize minimally invasive procedures when considering treatment options, indicating a strong interest in solutions like TAVR [5] - 75% of women are likely to inquire about more effective treatment options if presented with alternatives [5] Initiatives for Improvement - Medtronic and Women as One are launching educational campaigns and clinical trials to enhance health equity for women with heart valve disease [6] - The commitment to address healthcare inequities is emphasized through partnerships with clinical communities and organizations [6] Context on Aortic Stenosis - Aortic stenosis affects 1.5 million people in the U.S., with untreated symptomatic severe aortic stenosis leading to a two-year average survival rate [7] - Women face higher mortality rates from aortic stenosis compared to men, despite a longer life expectancy [7]

The most recent trading session ended with Medtronic (MDT) standing at $83.92, reflecting a -1.27% shift from the previouse trading day's closing. This change lagged the S&P 500's daily loss of 1.23%. Meanwhile, the Dow experienced a drop of 1.36%, and the technology-dominated Nasdaq saw a decrease of 1.4%.Heading into today, shares of the medical device company had lost 0.64% over the past month, outpacing the Medical sector's loss of 1.23% and lagging the S&P 500's gain of 1.61% in that time.The investmen ...